Any medicine will receive its marketing authorisation only when the pharmaceutical company has demonstrated that the innovation is efficient, of high quality and safe for the users. In Europe, a large share of the pharmaceutical industry’s investments – about 30 billion euro – goes to medicine R&D.
Good research conditions
Pharma Industry Finland PIF has 15 years of statistics on the research done by the pharmaceutical industry in Finland. They show that Finland has a good and long reputation as an interesting country from the pharmaceutical research perspective.
However, we now see some worrying phenomena and trends:
- Research volumes are decreasing and the money spent on them is less than it used to be.
- Fewer patients receive the most novel therapies as early as possible.
- Society has lost some of the therapies given in the form of trial medicines.
- Pharmaceutical companies reduce the number of clinical trial experts in Finland.
To turn the trend, we need to develop the operating environment of pharmaceutical research. This would attract more pharmaceutical research to Finland also in the future.
Number of Trials and Patients in Finland 2016
Trials by ATC Class 2016
Patients by ATC Class 2016
Registry Studies Change 2016
R&D Costs in Europe
R&D Costs in Europe, US and Japan
New Molecular Entities in Europe, US and Japan
R&D Share of Investments in Different Fields
Life Cycle of Product